UNITED LAB (03933.HK): NMPA Accepts Filing for IDegLira; First Chinese Biosimilar Applicant

NewTimeSpace News: On 24 September 2026, The United Laboratories International Holdings Limited (the "Company") voluntarily announced that insulin degludec and liraglutide injection (IDegLira), independently developed by Zhuhai United Pharmaceuticals Co., Ltd., a wholly-owned subsidiary of the Company, had its marketing registration application accepted by the National Medical Products Administration of China, with acceptance number CXSS2600154; the Company is the first enterprise in China to submit a marketing registration application for an insulin degludec/liraglutide biosimilar.

The announcement disclosed that IDegLira is a long-acting fixed-dose combination glucose-lowering therapy composed of basal insulin degludec (IDeg) and the glucagon-like peptide-1 (GLP-1) analogue liraglutide; the two components retain their respective pharmacokinetic profiles within the combination, achieving complementary advantages and synergistic effects that overcome the limits of monotherapy, delivering all-day steady glucose control, markedly improving glycaemic goal attainment, while balancing weight management and hypoglycaemia risk control. Requiring only one subcutaneous injection daily versus monotherapy or combination regimens, it substantially simplifies the dosing regimen and improves long-term adherence, offering type 2 diabetes patients a more efficient, safe and convenient integrated treatment option.

The Company stated that the marketing registration application marks another important achievement in the field of diabetes treatment; the Company will continue to devote itself to new product development, focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, deepen its presence in chronic disease treatment, serve clinical needs and benefit patients with better products and a more complete pipeline, and expects to create greater returns for the Company and its shareholders.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.